Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results


Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H’25

Excerpt from:
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results

Related Posts